Your browser doesn't support javascript.
loading
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
Kröger, N; Bornhäuser, M; Stelljes, M; Pichlmeier, U; Trenschel, R; Schmid, C; Arnold, R; Martin, H; Heinzelmann, M; Wolschke, C; Meyer, R G; Bethge, W; Kobbe, G; Ayuk, F; Gökbuget, N; Hölzer, D; Zander, A; Beelen, D.
Afiliación
  • Kröger N; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Bornhäuser M; Department of Hematology/Oncology, University Hospital Dresden, Dresen, Germany.
  • Stelljes M; Department of Hematology/Oncology, University Hospital Münster, Münster, Germany.
  • Pichlmeier U; CTS-Clinical Trial Solutions, Wedel, Germany.
  • Trenschel R; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
  • Schmid C; Department of Hematology/Oncology, Community Hospital, Augsburg, Germany.
  • Arnold R; Department of Hematology/Oncology, University Hospital Charité, Berlin, Germany.
  • Martin H; Department of Hematology/Oncology, University Hospital, Frankfurt, Germany.
  • Heinzelmann M; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Wolschke C; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Meyer RG; Department of Hematology/Oncology, University Medical Center Mainz, Mainz, Germany.
  • Bethge W; Department of Hematology/Oncology, University Hospital, Tübingen, Germany.
  • Kobbe G; Department of Hematology/Oncology, University Hospital, Düsseldorf, Germany.
  • Ayuk F; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Gökbuget N; Study Office German ALL Study Group (GMALL), Frankfurt, Germany.
  • Hölzer D; Study Office German ALL Study Group (GMALL), Frankfurt, Germany.
  • Zander A; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Beelen D; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
Bone Marrow Transplant ; 50(12): 1503-7, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26367236
ABSTRACT
TBI-based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with ALL. We investigated toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide and cyclophosphamide for ALL within a prospective study. Major inclusion criteria were CR and non-eligibility for TBI. Fifty patients with a median age of 46.5 years (range, 18-64) were included. Donors were HLA-identical sibling (n=8), matched (n=42) or mismatched (n=10) unrelated. The toxicity was moderate, resulting in a cumulative incidence of non-relapse mortality (NRM) at 1 year of 8% (90% confidence interval 2-15%). Acute GvHD grade II-IV and grade III/IV was noted in 53% and 14%, respectively. Chronic GvHD at one year was seen in 41%. After a median follow-up of 24 months the cumulative incidence of relapse was 36% (90% confidence interval 24-48) and 51% (90% confidence interval 37-65) at 1 and 2 years, respectively. The estimated 2-year disease-free and overall survivals were 36 and 48%, respectively. Treosulfan, etoposide and cyclophosphamide followed by AHSC has a favorable toxicity profile with low NRM and therefore represents a potential alternative regimen for ALL in 1. CR (NCT00682305).
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Acondicionamiento Pretrasplante / Agonistas Mieloablativos / Trasplante de Células Madre / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Acondicionamiento Pretrasplante / Agonistas Mieloablativos / Trasplante de Células Madre / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2015 Tipo del documento: Article